
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More